Sentences with phrase «uncertainty over the effect»

Due to the uncertainty over the effect of roller coasters on pregnancy, the American Pregnancy Association recommends avoiding these rides no matter how far along you are in your pregnancy.

The state has a $ 4.4 billion dollar deficit, and there's uncertainty over the effects of the federal tax overhaul on the state's finances, as well as possible big funding cuts by President Trump and Congress.

The state has a $ 4.4 billion deficit, and there's uncertainty over the effects of the federal tax overhaul on the state's finances, as well as possible big funding cuts by President Trump and Congress.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These short - term factors include: unclear payrolls data due to weather effects, uncertainty over the leadership of the Fed and comments of a potential 10 percent repatriation tax for U.S. firms, according to Gallo.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

The combined effect of this uncertainty overhang — from global trade tensions to domestic debt growth to tax law changes to interprovincial disputes over east - west pipeline access — has weighed on Canadian investment activity.

When asked which key events have had the greatest effect on the industry over the past year, respondents named mergers and acquisitions, which have created some instability and uncertainty.

In addition, there is considerable uncertainty over the estimated effects of business incentives that are services to business, such as customized job training, as relatively few studies have looked at such services.

The combined effect of this uncertainty overhang — from global trade tensions to domestic debt growth to tax law changes to interprovincial disputes over east - west pipeline access — has weighed on Canadian investment activity.

Despite uncertainty over the «Olympics effect» on cultural institutions in 2012, the year proved golden for Tate Modern which went on to welcomed 5.3 m visitors through its doors, the most in its history.

And as for IPCC changing conclusions this has happened many times — Lindzen used to point to statements about upper tropospheric water vapour for instance that became less confident from the 1990, 1995 and 2001 reports, similarly uncertainty in aerosol indirect effects has clearly grown over time.]

With the combination of (a) complexities = uncertainties and (b) time lags and lengths of effects over decades and centuries, climate - change grasp and responsible response are really tough to communicate.

Its impact remains clouded with scientific uncertainty, its effects will be felt over generations, and it is being amplified by everything from microwaving a frozen dinner to bringing electricity to an Indian village.

Figure 1: Gillett et al. attributable temperature changes due to greenhouse gases (red), other anthropogenic effects (green), and natural effects (blue) over each of the periods indicated in °C, based on the standard regression over the 1851 — 2010 period, with their associated uncertainties (vertical black lines).

Contrary to what Peter Taylor says in his book, it is well known that sulphate aerosols created in the atmosphere from fossil fuel combustion were a major influence on the small cooling trend from 1940, although uncertainties remain over the scale of the effect.

If we have concerns over how much CO2 effects the flux, which makes it an overall climate response or feedback parameter, then we might also consider the uncertainty in the 3.7 number.

Just seems on top of the un / certainty pick - ems (uncertainty about negative or positive feedback) or the other of gritty hinges we see are at the «core» of the issue that we're almost assuming we can explain the last 14,000 years in climate history to a resolution of a decade and rule out all factors effecting all changes over that time prior to 1850 effectively when we hear statements «high» (most, likely, probably, etc) certainties of understanding what we are seeing being used to support invoking PP.

However, another source of uncertainty in the monthly mean zonal cloud radiative effects comes from the low frequency of clear - sky occurrence, when averaging over regions that correspond to the spatial resolution of general circulation models.

• Poles to tropics temperature gradient, average temp of tropics over past 540 Ma; and arguably warming may be net - beneficial overall • Quotes from IPCC AR4 WG1 showing that warming would be beneficial for life, not damaging • Quotes from IPCC AR5 WG3 stating (in effect) that the damage functions used for estimating damages are not supported by evidence • Richard Tol's breakdown of economic impacts of GW by sector • Economic damages of climate change — about the IAMs • McKitrick — Social Cost of Carbon much lower than commonly stated • Bias on impacts of GHG emissions — Figure 1 is a chart showing 15 recent estimates of SCC — Lewis and Curry, 2015, has the lowest uncertainty range.

We show that (i) Siberian station temperature adjustments were up to 1.3 °C for decadal means before 1940, (ii) tree - ring detrending effects in the order of 0.620130.8 °C, and (iii) calibration uncertainties up to about 0.4 °C over the past 110 years.

Each effect is given in terms of its impact on the mean airborne fraction over the simulation period (typically 1860 to 2100), with bars showing the uncertainty range based on the ranges of effective sensitivity parameters given in Tables 7.4 and 7.5.

«Given this uncertainty [over the environmental and economic effects of CO2 emissions], and the historic failure of central planning to do anything other than undermine economic welfare, the editor, Colin Robinson, one of the country's leading energy economists, argues that it is prudent to proceed with caution.

Overall, the synopsis emphasized the positive effects of climate change over the negative, the uncertainty surrounding predictions of future change rather than the emerging consensus and the low end of harmful impact estimates rather than the high end.

These properties will be considered riskier investments; potential buyers will have uncertainty over potential health risks and the effect of the contamination on the future value of the property.

From the perspective of The International Stock Exchange (TISE), there have been three significant developments over the last 12 months: the impact of the EU Market Abuse Regulation which came into effect on 3 July 2016; the TISE expansion to the Isle of Man (and accompanying rebrand); and, inevitably, Brexit uncertainty.

It has created considerable uncertainty over the priority status afforded to pension plan wind - up deficits, particularly in insolvency proceedings involving the plan sponsor, and the effects on availability of credit for all organizations that provide defined benefit pension plans for their employees.

Also the effect of paternity uncertainty may weaken the bond between paternal siblings, making individuals unconsciously prefer their genetically more certain and maternal kin ties over less certain and paternal kin ties (Laham et al., 2005).

Since it took effect May 1, 2009, the Home Valuation Code of Conduct (HVCC) has generated significant commentary among real estate professionals, appraisers, and lenders — as well as plenty of uncertainty over exactly what the agreement does and does not allow.